SparingVision raises 75 million euros in Series B financing.

14 September 2022

France-based SparingVision, a portfolio company of venture capital firm 4BIO Capital that is focussed on developing vision-saving treatments for ocular diseases, has raised 75 million euros ($75.9 million) in a Series B financing.

The round was co-led by Jeito Capital and UPMC Enterprises, with additional participation from Bpifrance, the RD fund, venture arm of Foundation Fighting Blindness, Ysios Capital, and 4BIO. The financing extends SparingVision’s cash runway to the second half of 2025.

"Laser-focused on building the world’s leading portfolio of genomic medicines in the ocular space"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK